Trevi Therapeutics
TRVI
164 hedge funds and large institutions have $1.18B invested in Trevi Therapeutics in 2025 Q3 according to their latest regulatory filings, with 35 funds opening new positions, 65 increasing their positions, 42 reducing their positions, and 23 closing their positions.
89% more capital invested
Capital invested by funds: $627M → $1.18B (+$556M)
55% more repeat investments, than reductions
Existing positions increased: 65 | Existing positions reduced: 42
52% more first-time investments, than exits
New positions opened: 35 | Existing positions closed: 23
8.45% more ownership
Funds ownership: 97.75% → 106.2% (+8.4%)
7% more funds holding
Funds holding: 153 → 164 (+11)
14% less funds holding in top 10
Funds holding in top 10: 7 → 6 (-1)
48% less call options, than puts
Call options by funds: $8.43M | Put options by funds: $16.3M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Viking Global Investors
Stamford,
Connecticut
|
+$26.9M |
| 2 |
Morgan Stanley
New York
|
+$24.6M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
+$23.1M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$22M |
| 5 |
Marshall Wace
London,
United Kingdom
|
+$17.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WP
Woodline Partners
San Francisco,
California
|
-$29.6M |
| 2 |
Balyasny Asset Management
Chicago,
Illinois
|
-$13M |
| 3 |
SL
Siren LLC
Greenwich,
Connecticut
|
-$10.5M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$9.12M |
| 5 |
OCA
Octagon Capital Advisors
New York
|
-$6.43M |
TRVI Hedge Fund Activity: Q3 2025 in Review
164 of the 7,621 institutional investors tracked by Wall St. Rank reported a position in Trevi Therapeutics (TRVI) for Q3 2025, worth a combined $1.18B — up 89% from $627M a quarter earlier.
Buyers outnumbered sellers: 35 funds opened new TRVI positions and 23 closed out — a net gain of 12 holders — while 65 added to existing stakes and 42 trimmed.
The largest buyer was Viking Global Investors, adding an estimated $26.9M. The largest seller was Woodline Partners, cutting an estimated $29.6M.
- 164 institutional investors held Trevi Therapeutics (TRVI) as of Q3 2025, up from 153 in Q2 2025.
- Funds reported $1.18B of Trevi Therapeutics stock for Q3 2025, up 89% quarter-over-quarter.
- 35 funds opened new Trevi Therapeutics positions in Q3 2025 and 23 closed out, a net change of +12 holders.
- The largest Trevi Therapeutics buyer in Q3 2025 was Viking Global Investors, an estimated $26.9M added.
- The largest Trevi Therapeutics seller in Q3 2025 was Woodline Partners, an estimated $29.6M sold.
Based on aggregated 13F filings for Q3 2025.